On June 7, Biogen’s (BIIB) Aduhelm (aducanumab) was approved through the FDA’s accelerated approval process for treatment of Alzheimer’s offering hope to 6 million who suffer from the debilitating cognitive…
Stay informed with Paul’s unique perspective on healthcare happenings, from policies and politics to innovations and investments. Subscribe today to the Keckley Report and be the first to receive Paul’s weekly insights and special reports.